Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
227 articles on this topic
-
MOTS-c Before and After: What Research Shows
MOTS-c before and after photos are not clinical evidence. Human research has measured exercise and metabolic markers, but no completed study has published visible results from giving native MOTS-c—the exact peptide, not an altered analogue—to people.
-
PT-141 10mg Vial: What That Number Means
Ten milligrams describes what is in the whole vial. It does not tell you what to draw up, how many uses you have, or how a nasal product compares; those answers come from the prescription and pharmacy label.
-
Semaglutide Type 1 Diabetes: Guidance Has Limits
New 2026 guidance treats GLP-1 therapy as a possible obesity tool for some adults with type 1 diabetes, not as a replacement for insulin. The evidence is promising but small, and semaglutide is not approved to treat type 1 diabetes.
-
Sermorelin Half-Life: About 11 to 12 Minutes
Sermorelin leaves the bloodstream in minutes, but the growth-hormone pulse it starts can last for hours. Those are two different clocks, and neither is a personal dosing or drug-testing deadline.
-
Where to Inject MOTS-c: What the Evidence Says
The available human trial records point to a subcutaneous shot into the fatty layer beneath the skin. The pharmacy label and prescriber—not an online injection map—set the site for a specific MOTS-c preparation.
-
Novo Nordisk Lilly Lawsuit: What It Doesn't Decide
The fight is about how Zepbound ads frame a head-to-head trial after a higher Wegovy dose reached the market. It is not a court verdict on which medication is better for you.
-
Semaglutide News Update: September 2026
New child-trial results, heart-failure guidance, access changes and a June label update—what each means for a semaglutide prescription.
-
Compounded Tirzepatide Side Effects: What Changes?
Most side effects come from tirzepatide itself. Compounding can add a second layer of risk through concentration, measurement, added ingredients, sterility, and potency.
-
Does Tesamorelin Build Muscle? What Trials Show
Tesamorelin raised lean mass modestly in trials of adults with HIV-related lipodystrophy, but that is not proof of bigger or stronger muscles. It has not been shown to build muscle in healthy lifters.
-
Oral TB-500: Why Capsules Lack Human Evidence
There is no human evidence that a TB-500 capsule delivers intact peptide into the bloodstream. The published TB-500 and thymosin beta-4 work used injected or topical routes, so a capsule label cannot prove absorption or an effect.
-
SS-31 Protocol: What the Trials Actually Used
There is no single SS-31 cycle supported by human research. The useful evidence is narrower: a labeled plan for one rare disease and several trial schedules that cannot be copied into personal dosing advice.
-
Tesamorelin Before and After: The Study Timeline
Expect an early lab signal, not a one-month change in the mirror. The strongest trials measured deep abdominal fat at 26 and 52 weeks, all in adults with HIV-associated lipodystrophy.
-
Tirzepatide for Seniors: What New 2026 Data Show
Age 65 alone does not rule out tirzepatide. New 2026 research is reassuring, but adults over 75 remain underrepresented and the safest decision turns on muscle reserve, hydration, kidney health and other medicines.
-
When to Take Sermorelin: Why Bedtime Is Common
Bedtime is the usual convention because the body's largest growth-hormone pulse often follows deep sleep. It is a rhythm to work with, not proof that one clock time fits everyone.
-
FDA Telehealth Compounded Drugs: 5 Red Flags
FDA says telehealth sites must not present a compounded drug as a generic, a brand equivalent, or an agency-reviewed product. Here is what an honest prescription page should make clear.
-
DSIP Nasal Spray: What the Human Research Says
A DSIP nasal spray appears in one small human experiment, but no published human nasal PK or sleep trial validates the format. Promise currently lists DSIP as an injection, not a spray.
-
Is Tesamorelin a Steroid? No—It's a GHRH Peptide
Tesamorelin is a peptide signal, not an anabolic steroid or growth hormone itself. It prompts the pituitary to release growth hormone, but sport rules still prohibit it.
-
Kisspeptin vs PT-141: They Work Differently
Kisspeptin and PT-141 both enter libido conversations, but they act on different systems and do not share the same evidence. PT-141 has larger trials and an approved branded product; kisspeptin's human data are smaller and earlier.
-
Tesamorelin 10 mg: What the Vial Number Means
A tesamorelin 10 mg label describes the total peptide in the vial, not the amount in one injection. The prescribed amount, liquid volume, and days of supply come from the pharmacy label and provider's plan.
-
Tirzepatide Before and After: An Honest Timeline
Tirzepatide before and after photos can't tell you what caused a change. The trials give a more useful timeline: early appetite shifts, months of gradual change, and a later plateau that varies widely.
Page 3 of 12 · 227 articles